Velcade (bortezomib) Information

The Food and Drug Administration has approved Velcade to treat a type of cancer called multiple myeloma. Velcade should only be used in people who have already been treated with two other types of chemotherapy (drugs used to kill cancer cells), and whose cancer has still progressed on the most recent therapy.  Velcade is a new type of cancer drug called a proteasome inhibitor. Proteasomes are enzymes found in cells, and play a role in regulating cell function and growth. Velcade blocks the activity of proteasomes. This blockade can lead to death of cancer cells. 

• Velcade (bortezomib) is Approved for Initial Treatment of Patients with Multiple Myeloma (6/24/2008)
• Label and Approval Letter from Drugs@FDA
• FDA approves bortezomib (Velcade) for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy (12/8/2006)
• FDA Press Release: FDA Approves Velcade for Multiple Myeloma Treatment. (5/13/2003)
• Questions and Answers on Velcade
• Patient Information Sheet

Back to Top     Back to DrugIndex

PDF requires the free Adobe Acrobat Reader

Created: May 13, 2003; Last Updated: June 24, 2008

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page

FDA/Center for Drug Evaluation and Research